Fertility monitoring following cancer treatment should include menstrual cycle information, which can be of value in detecting fertility irregularities, as well as hormone analyses, including anti-Mullerian hormone (AMH), a marker for ovarian reserve, and if indicated the antral follicle count (AFC) measured by ultrasound by a reproductive specialist. Here, AMH is linked to cancer.